A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00653939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel, and Bevacizumab ± Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab ± CA4P in Subjects With Chemotherapy Naïve Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients with chemotherapy naïve non-small cell lung cancer (NSCLC). This is a randomized parallel arm study. All participants will receive carboplatin, paclitaxel and bevacizumab, and half will additionally receive CA4P. Patients who complete the first 6 cycles of therapy and have not experienced disease progression will receive maintenance therapy with bevacizumab alone or with bevacizumab plus CA4P. The rationale for this study is the potential additive or synergistic actions of vascular disrupting agents like CA4P with anti-angiogenic agents like bevacizumab.
Study identification
- NCT ID
- NCT00653939
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Oct 2011 (Actual)
- Last update posted
- Feb 9, 2015
2008 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southbay Oncology Hematology | Campbell | California | 95008 | — |
| Pacific Coast Hematology and Oncology Medical Group | Fountain Valley | California | 92708 | — |
| UCLA Division of Hematology and Oncology | Los Angeles | California | 90095 | — |
| Bay Area Cancer Research Group, LLC | Pleasant Hill | California | 94523 | — |
| Boca Raton Comprehensive Cancer Center | Boca Raton | Florida | 21020 | — |
| Kentuckiana Cancer Institute | Louisville | Kentucky | 40202 | — |
| Lahey Clinic Medical Center | Burlington | Massachusetts | 01805 | — |
| The Center for Cancer and Hematologic Disease | Cherry Hill | New Jersey | 08003 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Signal Point Clinical Research | Middletown | Ohio | 45042 | — |
| Blueridge Cancer Care | Salem | Virginia | 24153 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Mary Babb Randolph Cancer Center-Clinical Trials Unit | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00653939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2015 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00653939 live on ClinicalTrials.gov.